Critical Outcome Technologies Inc.
TSX VENTURE : COT

Critical Outcome Technologies Inc.

June 13, 2008 09:05 ET

Critical Outcome Technologies Inc. Identifies a Novel Mechanism of Action for COTI-2

LONDON, ONTARIO--(Marketwire - June 13, 2008) - Critical Outcome Technologies Inc. (TSX VENTURE:COT), announced today that the Company has received confirmatory experimental results that have identified a novel and potentially first in class mechanism of action (MOA) for its lead cancer drug candidate, COTI-2. Experiments conducted in triplicate have confirmed that COTI-2 has a profound effect on caspase-9 activation through inhibition of Akt/PKB. The resulting activation of caspase 9 leads to a vigorous apoptosis or programmed cell death in cancer cells.

"The confirmation of a novel MOA for COTI-2 represents a significant advancement for Critical Outcome Technologies Inc. (COTI) and our anti-cancer drug development programme. Akt and related pathways constitute an important area of ongoing research and considerable commercial interest for many pharmaceutical organizations. This latest data combined with our previously accumulated test data puts our company in the position to bolster our COTI-2 marketing campaign with a commercially appealing data package for our prospective partners," said Dr. Wayne Danter, President and CSO of COTI.

Notice to Readers

Information contained in this press release may contain certain statements which constitute "forward-looking statements" within the meaning of the Securities Act (Ontario) and applicable securities laws. Specifically, the statement "novel and potentially first in class mechanism of action (MOA)" is a forward-looking statement. This statement was based upon research test results on the molecule, an understanding of the current therapies both in use and in trials for cancer and includes patenting research and the socializing of the data package with a significant number of Pharmaceutical companies of various sizes. Forward-looking statements, by their nature, are not guarantees of future performance and are based upon management's current expectations, estimates, projections and assumptions. COTI operates in a highly competitive environment that involves significant risks and uncertainties which could cause actual results to differ materially from those anticipated in these forward-looking statements. Management of COTI considers the assumptions on which these forward-looking statements are based to be reasonable, but as a result of the many risk factors, cautions the reader that actual results could differ materially from those expressed or implied in these forward-looking statements. Information in this press release should be considered accurate only as of the date of the release and may be superseded by more recent information disclosed in later press releases, filings with the securities regulatory authorities or otherwise.

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI's business is focused on the discovery and pre-clinical development of libraries of novel, optimized lead molecules for the treatment of specific cancers, HIV and multiple sclerosis. Currently, five targeted libraries of lead compounds (small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, colorectal cancer, and acute myelogenous leukemia in adults) are under active development.

For further information, please visit the website www.criticaloutcome.com.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information